Vernalis plc is a research and development-stage pharmaceutical company. Vernalis has one marketed product and a portfolio of development and drug discovery programmes. Vernalis has 10 active collaborations, four covering programmes in pre-clinical through to Phase II development and six drug discovery collaborations. Its commercial pipeline includes CCP1, CCP2 and CCP3. The Company operates in the United Kingdom, Rest of Europe, North America and Rest of the World. Frovatriptan is a selective 5-HT1B/1D receptor agonist approved as an acute oral treatment for migraine headache and its associated symptoms. As of December 31, 2011, the Company had two development products in the CNS therapeutic area. As of December 31, 2011, it had four development programmes in cancer. During the year ended December 31, 2011, the Company reacquired the rights of V1003 from Reckitt Benckiser, in order to return them to Archimedes, which was completed, on February 21, 2012.